NEW YORK (GenomeWeb News) – Qiagen said today that it has acquired UK-based companion diagnostics firm DxS in a deal that could be worth as much as $130 million.

Qiagen said that the acquisition provides it with a strong leadership position in the personalized healthcare arena.

Further supporting that claim, Qiagen also disclosed that it has more than 15 collaborations with pharmaceutical companies to develop and/or market companion diagnostic products, which it believes is the deepest such portfolio in the industry.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.